Bioventus Inc
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 34.7% | 36.3% | 31.7% | 31.5% | 32.7% | 33.2% | 34.2% | 31.8% | 33.0% | 31.9% | 32.1% | 31.0% | 32.0% | |
| 65.3% | 63.7% | 68.3% | 68.5% | 67.3% | 66.8% | 65.8% | 68.2% | 67.0% | 68.1% | 67.9% | 69.0% | 68.0% | |
| 2.5% | 2.4% | 2.0% | 2.8% | 2.7% | 2.1% | 2.4% | 2.1% | 2.1% | 1.9% | 1.9% | 2.1% | 2.0% | |
| 57.8% | 55.0% | 60.6% | 62.7% | 58.4% | 56.4% | 59.3% | 53.6% | 56.7% | 52.4% | 59.3% | 54.0% | 55.4% | |
| 63.3% | 62.9% | 64.5% | 89.3% | 64.4% | 61.6% | 61.7% | 55.6% | 58.2% | 54.3% | 61.2% | 56.5% | 57.4% | |
| 2.0% | 0.9% | 3.8% | -20.8% | 2.9% | 5.2% | 4.0% | 12.6% | 8.7% | 13.8% | 6.7% | 12.5% | 10.6% | |
| 8.4% | 7.6% | 8.0% | 6.6% | 6.9% | 5.9% | 6.1% | 5.1% | 4.5% | 3.4% | 3.3% | 2.7% | 3.4% | |
| -6.8% | -6.2% | -4.2% | -27.5% | -3.5% | 0.2% | -2.8% | 7.0% | 3.4% | 9.0% | 3.4% | 10.0% | 6.6% | |
| 0.5% | -0.6% | 0.7% | -4.9% | 0.4% | 0.4% | -0.1% | 0.7% | 0.5% | -2.0% | 0.4% | -13.6% | -3.9% | |
| -6.0% | -4.5% | -3.8% | -17.0% | -3.5% | -0.1% | -2.1% | 5.1% | 2.3% | 9.3% | 2.4% | 21.8% | 9.4% | |
| 13.0% | 10.6% | 12.9% | -12.3% | 12.2% | 14.1% | 12.9% | 20.2% | 16.0% | 19.7% | 15.2% | 12.6% | 16.0% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.